Sugi Predict

Sugi Predict / Compounds / SCHEMBL746119

SCHEMBL746119

SCHEMBL746119

CNC(=O)Nc1c[c]ccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ RECQL P46063 1/20 0.47
▸ KMT2A Q03164 3/20 0.42
▸ TP53 P04637 1/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ MAPT P10636 3/20 0.40
▸ POLB P06746 2/20 0.39
▸ TAAR1 Q96RJ0 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CASP3 P42574 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MAOA P21397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2518709 0.83 SMN1; SMN2 (0.65) SMN1; SMN2KMT2ATP53EPHX1TSHR
SCHEMBL1419259 0.82 NPC1 (0.42) ALDH1A1SMN1; SMN2KMT2ATP53EPHX1
SCHEMBL6990986 0.82 NPC1 (0.44) ALDH1A1SMN1; SMN2KMT2ATP53EPHX1
SCHEMBL50031 0.81 HSD17B10 (0.57) ALDH1A1SMN1; SMN2KMT2ATSHRMAPT
SCHEMBL1419116 0.81 EPHX1 (0.43) ALDH1A1SMN1; SMN2KMT2ATP53EPHX1
SCHEMBL2531539 0.79 EPHX2 (0.41) SMN1; SMN2KMT2ATP53EPHX1TSHR
SCHEMBL6700173 0.78 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2KMT2ATP53EPHX1
SCHEMBL2122731 0.78 SMN1; SMN2 (0.59) ALDH1A1SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL359677 0.78 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2KMT2AMAPTPOLB
SCHEMBL6960682 0.78 MAPT (0.53) ALDH1A1SMN1; SMN2KMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130116230-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2013-05-09 — — US claimed
US-8362003-B2 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORPORATION (US) 2013-01-29 — — US claimed
EP-2431357-A2 3-Aminopyrrolidine Derivatives as Modulators of Chemokine Receptors Incyte Corporation (US) 2012-03-21 — — EP claimed
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION 2011-10-13 — — US claimed
EP-1565436-A4 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORP (US) 2007-07-18 — — EP claimed
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors INCYTE HOLDINGS CORPORATION 2006-11-09 — — US claimed
JP-2006516145-A — — 2006-06-22 — — JP claimed
CN-1741994-A 3-aminopyrrolidine derivatives as modulators of chemokine receptors INCYTE CORP (US) 2006-03-01 — — CN claimed
US-6967197-B2 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-22 — — US claimed
EP-1565436-A2 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2005-08-24 — — EP claimed
CN-1188404-C Cyclic compound FUJISAWA PHARMACEUTICAL CO (JP) 2005-02-09 — — CN claimed
WO-2004050024-A2 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS INCYTE CORPORATION (US) 2004-06-17 — — WO claimed
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 — — US claimed
CN-1425010-A Cyclic compound FUJISAWA PHARMACEUTICAL CO (JP) 2003-06-18 — — CN claimed
WO-2003018019-A2 NEW USE OF CYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-06 — — WO claimed
EP-1259499-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 — — EP claimed
WO-2001060808-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 — — WO claimed
US-20200109139-A1 PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2020-04-09 — — US disclosed
EP-0310125-A2 Silver halide color photographic material FUJI PHOTO FILM CO., LTD. (JP) 1989-04-05 — — EP disclosed
EP-0296606-A2 Silver halide color photographic materials and processing method FUJI PHOTO FILM CO., LTD. (JP) 1988-12-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116230-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CXCR3, CCR5 ALDH1A1 2447/4885SMN1; SMN2 4846/4885RECQL 2689/4885
US-20060252751-A1 3-Aminopyrrolidine derivaties as modulators of chemokine receptors CCR2, CXCR3, CCR5 ALDH1A1 2501/4885SMN1; SMN2 4815/4885RECQL 2767/4885
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors MMP9, MMP1, MMP3 ALDH1A1 543/4885SMN1; SMN2 3844/4885RECQL 4177/4885
US-20200109139-A1 PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF TYMP, TYMS, DPYD ALDH1A1 709/4885SMN1; SMN2 1532/4885RECQL 877/4885
US-20110251168-A1 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS CCR2, CXCR3, CCR5 ALDH1A1 2447/4885SMN1; SMN2 4846/4885RECQL 2689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.